PLSE - NASDAQ
Pulse Biosciences, Inc.
$24.99
+1.3%Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
At a Glance
Live Snapshotplse
Total Liabilities and Equity
Last Annual Value
96.11M
3-Year CAGR
7%
5-Year CAGR
18%
10-Year CAGR
21%
Pulse Biosciences, Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Pulse Biosciences, Inc. NASDAQ:PLSE | 96.11M | 17.6% | 12.1% | 13.8% | |
 NovoCure Limited NASDAQ:NVCR | 804.33M | -11.1% | -6.7% | 11.0% | |
 Nektar Therapeutics NASDAQ:NKTR | 280.41M | -11.0% | -24.2% | -6.8% | |
 Kestra Medical Technologies, Ltd. NASDAQ:KMTS | 295.74M | 97.0% | 57.5% | N/A | |
 OPKO Health, Inc. NASDAQ:OPK | 1.93B | -1.3% | -4.2% | -3.5% | |
 Dianthus Therapeutics, Inc. NASDAQ:DNTH | 530.92M | 43.6% | 22.8% | 46.9% | |
 Beta Bionics, Inc. NASDAQ:BBNX | 328.74M | 44.0% | N/A | N/A | |
 Atai Beckley Inc. NASDAQ:ATAI | 310.54M | 1.9% | -5.6% | N/A | |
 LifeMD, Inc. NASDAQ:LFMD | 70.41M | 6.4% | 7.1% | 56.7% | |
 STAAR Surgical Company NASDAQ:STAA | 461.62M | -1.9% | 5.9% | 21.6% |
Pulse Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your PLSE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.